Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase III studies
Clin Exp Dermatol 2024;49:793–800 doi: 1093/ced/llad329
Following discontinuation of secukinumab 150mg or 300mg, a proportion of patients sustained low PASI with clear or almost clear skin despite being drug free for up to 2 years. Patients with a shorter disease duration were less likely to relapse, further supporting the hypothesis that earlier intervention with secukinumab may result in long-term control of moderate-to-severe psoriasis.
As part of the FIXTURE/ERASURE extension studies, patients who achieved PASI75 at Week 52 were randomised 2:1 to continue their original secukinumab dose or switch to placebo. Patients whose symptoms relapsed during the extension study were switched back to their initial treatment. Patients were followed for up to 152 weeks.
Keywords:
